Sun Pharma inks pact with Lundbeck to market, distribute Vortioxetine in India

30 Mar 2022 Evaluate

Sun Pharmaceutical Industries has entered into an exclusive patent licensing agreement with H. Lundbeck A/S (Lundbeck) to market and distribute its own version of Vortioxetine in India under the brand name, ‘Vortidif’. The territory of the licensing agreement will only cover India.

Vortioxetine is a novel antidepressant with multimodal activity, which is approved to treat Major Depressive Disorder (MDD) in adults. The product is approved in over 80 countries, including the US, EU, Canada and Australia.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1849.05 -3.40 (-0.18%)
31-Oct-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1849.05
Dr. Reddys Lab 1274.25
Cipla 1553.20
Lupin 2184.00
Zydus Lifesciences 1001.85
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.